Cargando…

Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target

A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez, Irene L., Dello Russo, Cinzia, Novellino, Fabiana, Caso, Javier R., García-Bueno, Borja, Leza, Juan C., Madrigal, José L. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181823/
https://www.ncbi.nlm.nih.gov/pubmed/35682822
http://dx.doi.org/10.3390/ijms23116143
_version_ 1784723878950469632
author Gutiérrez, Irene L.
Dello Russo, Cinzia
Novellino, Fabiana
Caso, Javier R.
García-Bueno, Borja
Leza, Juan C.
Madrigal, José L. M.
author_facet Gutiérrez, Irene L.
Dello Russo, Cinzia
Novellino, Fabiana
Caso, Javier R.
García-Bueno, Borja
Leza, Juan C.
Madrigal, José L. M.
author_sort Gutiérrez, Irene L.
collection PubMed
description A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer’s disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer’s disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer’s disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer’s disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer’s disease.
format Online
Article
Text
id pubmed-9181823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91818232022-06-10 Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target Gutiérrez, Irene L. Dello Russo, Cinzia Novellino, Fabiana Caso, Javier R. García-Bueno, Borja Leza, Juan C. Madrigal, José L. M. Int J Mol Sci Review A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer’s disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer’s disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer’s disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer’s disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer’s disease. MDPI 2022-05-30 /pmc/articles/PMC9181823/ /pubmed/35682822 http://dx.doi.org/10.3390/ijms23116143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gutiérrez, Irene L.
Dello Russo, Cinzia
Novellino, Fabiana
Caso, Javier R.
García-Bueno, Borja
Leza, Juan C.
Madrigal, José L. M.
Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title_full Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title_fullStr Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title_full_unstemmed Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title_short Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
title_sort noradrenaline in alzheimer’s disease: a new potential therapeutic target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181823/
https://www.ncbi.nlm.nih.gov/pubmed/35682822
http://dx.doi.org/10.3390/ijms23116143
work_keys_str_mv AT gutierrezirenel noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT dellorussocinzia noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT novellinofabiana noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT casojavierr noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT garciabuenoborja noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT lezajuanc noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget
AT madrigaljoselm noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget